Aspen Neuroscience announces appointment of Damien McDevitt, PhD as President and Chief Executive Officer

SAN DIEGO, January 25, 2021 — Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, announced today that it has appointed biotech leader Damien McDevitt, PhD, as President and Chief Executive Officer. Dr. McDevitt will also be joining the company’s board of directors.

 “We are excited to welcome Damien to Aspen Neuroscience at a pivotal moment of growth and development for the company,” said Faheem Hasnain, Aspen Board Chairman. “His experience leading global teams through transformational periods will be critical to Aspen as we move into this new stage.”

 “I am honored to be joining Aspen Neuroscience, which is innovating at the intersection of regenerative medicine and neurosciences,” said Dr. McDevitt. “I’m excited about our mission to develop transformational medicines for Parkinson’s patients, who have very limited treatment options. Aspen is poised for its next chapter, with a very compelling pipeline developed by the great minds at Scripps, including lead product ANPD001, currently undergoing IND-enabling studies for the treatment of sporadic forms of Parkinson’s disease, and ANPD002, which combines gene correction and autologous neuron therapy, being studied for the treatment of genetic forms of Parkinson’s disease. We are excited to be building this world-class team in San Diego, a hub for R&D and life sciences, and in California, which is on the leading edge of regenerative medicine science.”

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.